Topline results are expected in November 2026 ahead of a planned sBLA submission.
Feature|Articles|June 9, 2025
- Vol 53 No 06
- Volume 53
- Issue 06
En bloc resection of bladder tumor: Is it the way forward?
Fact checked by: Benjamin P. Saylor, Strategic Content Lead
"As urologists, we are the gatekeepers, and we must always perform the best possible surgery to optimize oncological outcomes," writes Jeremy Teoh, MBBS, FRCSEd (Urol), FCSHK, FHKAM (Surgery).
Advertisement
Advertisement
More than 2 centuries ago, Philipp Bozzini invented the Lichtleiter, allowing urologists to visualize what is inside the bladder.1 About 1 century ago, Maximilian Stern invented the first resectoscope, which allows us to remove a bladder tumor with electrocautery.2 These 2 crucial elements empowered urologists to perform transurethral resection of bladder tumor (TURBT), a highly revolutionary approach given the limited resources that urologists had at that time.
Related to this article
In a POTOMAC subgroup analysis, durvalumab plus BCG reduced the risk of high-risk recurrence or death by 44% vs BCG alone in patients with papillary-only, BCG-naive NMIBC.
Andrea Necchi, MD, discusses how results from the CA017-078 trials compares with other perioperative immunotherapy trials in muscle-invasive bladder cancer.
Final phase 3 CA017-078 data show perioperative nivolumab plus GC did not significantly improve pCR (39.1% vs 29.6%) or EFS (HR, 0.94) vs GC alone in MIBC.
Perioperative durvalumab (Imfinzi) plus neoadjuvant enfortumab vedotin-ejfv (Padcev) cut the risk of EFS events by 49% and death by 42% in cisplatin-ineligible MIBC.
At a median follow-up of 60.9 months, median EFS was 74.1 months in the pembrolizumab arm and not reached in the placebo arm.
Michael S. Cookson, MD, MMHC, FACS, discusses how Anktiva’s expanded FDA approval may broaden bladder-preserving treatment options for BCG-unresponsive papillary-only NMIBC.
This approval expands the perioperative use of pembrolizumab plus enfortumab vedotin to all patients with MIBC, regardless of cisplatin eligibility.
Advertisement
Advertisement